The aim of the present study was to develop a diagnostic set of single-nucleotide polymorphisms (SNPs) for discriminating aspirin-exacerbated respiratory disease (AERD) from aspirin-tolerant asthma (ATA) using the genome-wide association study (GWAS) data; the GWAS data were filtered according to p-values and odds ratios (ORs) using PLINK software, and the 10 candidate SNPs most closely associated with AERD were selected, based on 100 AERD and 100 ATA subjects. Using multiple logistic regression and receiver-operating characteristic (ROC) curve analysis, eight SNPs were chosen as the best model for distinguishing between AERD and ATA. The relative risk for AERD in each subject was calculated based on the relative risk of each of the eight SNPs. Ten of the original 109,365 SNPs highly associated (filtered with p<0.001 and ORs) with the risk for AERD were selected. A combination model of the eight SNPs among the 10 SNPs showed the highest area under the ROC curve of 0.9. The overall relative risk for AERD based on the eight SNPs was significantly different between the AERD and ATA groups (p=2.802E-21), and the sensitivity and specificity were 78% and 88%, respectively. The candidate set of eight SNPs may be useful in predicting the risk for AERD.
Get full access to this article
View all access options for this article.
References
1.
BatemanE.D., HurdS.S., BarnesP.J., BousquetJ., DrazenJ.M., FitzGeraldM., GibsonP., OhtaK., O'ByrneP., PedersenS.E., PizzichiniE., SullivanS.D., WenzelS.E., ZarH.J.2008. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J, 31:143–178.
2.
BlancoS., Sanz-GarciaM., SantosC.R., LazoP.A.2008. Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein. PLoS One, 3:e1660.
3.
BoumanL., SchlierfA., LutzA.K., ShanJ., DeinleinA., KastJ., GalehdarZ., PalmisanoV., PatengeN., BergD., GasserT., AugustinR., TrumbachD., IrrcherI., ParkD.S., WurstW., KilbergM.S., TatzeltJ., WinklhoferK.F.2011. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ, 18:769–782.
4.
ChangH.S., ParkJ.S., JangA.S., ParkS.W., UhS.T., KimY.H., ParkC.S.2011. Diagnostic value of clinical parameters in the prediction of aspirin-exacerbated respiratory disease in asthma. Allergy Asthma Immunol Res, 3:256–264.
5.
ChoiJ.H., ParkH.S., OhH.B., LeeJ.H., SuhY.J., ParkC.S., ShinH.D.2004. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet, 114:337–344.
6.
ChristopherA., Haiman, Loïc LeMarchand, JenniferYamamato, DanielO., StramXin, ShengLaurence N., KolonelAnna H., WuDavid, ReichBrian E., Henderson. 2007. A common genetic risk factor for colorectal and prostate cancer. Nature Genetics, 39:954–956.
7.
CornfieldJ.1951. A method for estimating comparative rates from clinical data. Applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst, 11:1269–1275.
8.
De WeckA.L., SanzM.L., GamboaP.M., JermannJ.M., KowalskiM., MedralaW., Sainte-LaudyJ., SchneiderM.S., WeberJ.M., Wolanczyk-MedralaA.2010. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome: a multicenter study II. Basophil activation by nonsteroidal anti-inflammatory drugs and its impact on pathogenesis. J Investig Allergol Clin Immunol, 20:39–57.
9.
DevouassouxG., PachotA., LaforestL., DiasparraJ., FreymondN., Van GanseE., MouginB., PachecoY.2008. Galectin-10 mRNA is overexpressed in peripheral blood of aspirin-induced asthma. Allergy, 63:125–131.
10.
EastonDouglas F., EelesRosalind A.2008. Genome-wide association studies in cancer. Hum Mol Genet, 17:R109–R115.
11.
GollapudiR.R., TeirsteinP.S., StevensonD.D., SimonR.A.2004. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA, 292:3017–3023.
HirschhornJ.N., DalyM.J.2005. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet, 6:95–108.
15.
Jun, ZhangM.B., KaiF., Yu. 1998. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA, 280:1690–1691.
16.
KimB.S., ParkS.M., UhmT.G., KangJ.H., ParkJ.S., JangA.S., UhS.T., KimM.K., ChoiI.S., ChoS.H., HongC.S., LeeY.W., LeeJ.Y., ChoiB.W., ParkH.S., ParkB.L., ShinH.D., ChungI.Y., ParkC.S.2010. Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity. Pharmacogenet Genomics, 20:748–758.
LeeS.H., RhimT., ChoiY.S., MinJ.W., KimS.H., ChoS.Y., PaikY.K., ParkC.S.2006. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med, 173:370–378.
23.
MarquetteC.H., SaulnierF., LeroyO., WallaertB., ChopinC., DemarcqJ.M., DurocherA., TonnelA.B.1992. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis, 146:76–81.
24.
MasciaK., HaselkornT., DenizY.M., MillerD.P., BleeckerE.R., BorishL.2005. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol, 116:970–975.
25.
MinJ.W., JangA.S., ParkS.M., LeeS.H., LeeJ.H., ParkS.W., ParkC.S.2005. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest, 128:3127–3132.
26.
MoffattM.F., KabeschM., LiangL., DixonA.L., StrachanD., HeathS., DepnerM., von BergA., BufeA., RietschelE., HeinzmannA., SimmaB., FrischerT., Willis-OwenS.A., WongK.C., IlligT., VogelbergC., WeilandS.K., von MutiusE., AbecasisG.R., FarrallM., GutI.G., LathropG.M., CooksonW.O.2007. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature, 448:470–473.
27.
OhS.H., ParkS.M., ParkJ.S., JangA.S., LeeY.M., UhS.T., KimY.H., ChoiI.S., KimM.K., ParkB.L., ShinH.D., ParkC.S.2009. Association analysis of peroxisome proliferator-activated receptors gamma gene polymorphisms with aspirin hypersensitivity in asthmatics. Allergy Asthma Immunol, 1:30–35.
28.
ParkB.L., ParkS.M., ParkJ.S., UhS.T., ChoiJ.S., KimY.H., KimM.K., ChoiI.S., ChoiB.W., ChoS.H., HongC.S., LeeY.W., LeeJ.Y., ParkC.S., ShinH.D.2010. Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics. BMB Rep, 43:445–449.
29.
ParkJ.S., ChangH.S., ParkC.S., LeeJ.H., LeeY.M., ChoiJ.H., ParkH.S., KimL.H., ParkB.L., ChoiY.H., ShinH.D.2005. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics, 15:483–492.
30.
PicadoC., CastilloJA., MontserratJM., Agusti-VidalA.1989. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir, 2:127–129.
31.
PlantD., BowesJ., PotterC., HyrichK.L., MorganA.W., WilsonA.G., IsaacsJ.D., BartonA.2011. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum, 63:645–653.
32.
PurcellS., NealeB., Todd-BrownK., ThomasL., FerreiraM.A.et al.2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet, 81:559–575.
33.
RobertS., GhislainR., JohanR., ChristianD., LishuangS., DavidS., PhilippeB., DanielV., AlexandreB., SamyH., BeverleyB., BarbaraH., GuillaumeC., ThomasJ.H., AlexandreM., AlexeyV.P., MarcP., BarryI.P., DavidJ.B., DavidM., ConstantinP., PhilippeF.2007. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 445:881–885.
34.
RosesA.D.2008. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov, 7:807–817.
35.
SamterM., BeersR.1976. Concerning the nature of intolerance to aspirin. J Allergy, 40:281–293.
36.
SanakM., KielbasaB., BochenekG., SzczeklikA.2004. Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy, 34:1899–1904.
37.
SistromC.L., GarvanC.W.2004. Proportions, odds, and risk. Radiology, 230:12–19.
38.
StevensonD., Sanchez-BorgesM., SzczeklikA.2001. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol, 87:177–180.
39.
SzczeklikA., NizankowskaE., DuplagaM.2000. Natural history of aspirin-induced asthma. AIANE Investigators. European network on aspirin-induced asthma. Eur Respir J, 16:432–436.
40.
WataruS., YukoN., IkukoM., YushiH., ChiyomiI., MichiakiK., TakahisaK., TatsuhikoT., MasahikoW., AtsushiT., HiroyukiT., KenjiN., KazukoH., FumiyaO., TakeoY., HideshiK., SaburoS., MitsutoshiY., NobutakaH., MihoM., YusukeN., TatsushiT.2009. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics, 41:1303–1307.
41.
WillisC.M., WranaJ.L., KluppelM.2009. Identification and characterization of TGFbeta-dependent and -independent cis-regulatory modules in the C4ST-1/CHST11 locus. Genet Mol Res, 8:1331–1343.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
